Lapatinib Teva (Lapatinib)

Lapatinib is a targeted oral therapy used in HER2‑driven cancers. It is indicated for the following conditions:

• HER2‑positive metastatic breast cancer: improves progression‑free survival when combined with chemotherapy.
• HER2‑positive metastatic gastric cancer: used with capecitabine to delay disease progression.
• HER2‑positive early‑stage breast cancer (adjuvant setting): administered after surgery to reduce recurrence risk.

• Lapatinib binds to the intracellular tyrosine kinase domains of epidermal growth factor receptor (EGFR/ErbB1) and HER2 (ErbB2), preventing autophosphorylation and downstream signaling through the MAPK and PI3K/AKT pathways. This inhibition reduces tumor cell proliferation, survival, and angiogenesis, thereby slowing cancer growth.

Lapatinib may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Diarrhea: frequent loose stools, may require hydration.
• Rash: skin redness, often on trunk or extremities.
• Nausea: upset stomach, sometimes with vomiting.
• Fatigue: persistent tiredness affecting daily activities.
• Hand‑foot syndrome: redness or swelling of palms and soles.
• Headache: mild to moderate intensity.

Serious or Rare Side Effects

• Liver toxicity: elevated transaminases, jaundice.
• Cardiac dysfunction: decreased left‑ventricular ejection fraction.
• Interstitial lung disease: breathing difficulty, cough.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• QT interval prolongation: risk of arrhythmia.
• Severe diarrhea leading to dehydration.

Before initiating Lapatinib, clinicians should consider several safety measures.

• Liver monitoring: check hepatic enzymes regularly.
• Cardiac assessment: evaluate baseline ejection fraction and repeat as needed.
• Skin surveillance: watch for severe rash or mucosal lesions.
• Diarrhea management: treat early to prevent dehydration.
• Drug interactions: avoid strong CYP3A4 inhibitors or inducers without dose adjustment.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lapatinib interacts with several medicines that affect its metabolism or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase Lapatinib exposure.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
• Antacids containing aluminum or magnesium: can lower absorption if taken simultaneously.

Moderate Interactions (Monitor Closely)

• Warfarin: may enhance anticoagulant effect, monitor INR.
• Digoxin: possible increase in serum levels, check cardiac function.
• Statins metabolized by CYP3A4 (e.g., simvastatin): monitor for muscle toxicity.
• Proton pump inhibitors: may modestly affect drug levels, observe clinical response.